CAMBIA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Cambia patents expire, and when can generic versions of Cambia launch?
Cambia is a drug marketed by Assertio and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-four patent family members in twenty-three countries.
The generic ingredient in CAMBIA is diclofenac potassium. There are forty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cambia
A generic version of CAMBIA was approved as diclofenac potassium by TEVA on August 6th, 1998.
Summary for CAMBIA
| International Patents: | 34 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 54 |
| Clinical Trials: | 3 |
| Patent Applications: | 5,802 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CAMBIA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CAMBIA |
| What excipients (inactive ingredients) are in CAMBIA? | CAMBIA excipients list |
| DailyMed Link: | CAMBIA at DailyMed |
Recent Clinical Trials for CAMBIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Scripps Health | Phase 4 |
| Depomed | Phase 4 |
| Mayo Clinic | Phase 2/Phase 3 |
Pharmacology for CAMBIA
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
| Physiological Effect | Decreased Prostaglandin Production |
Anatomical Therapeutic Chemical (ATC) Classes for CAMBIA
Paragraph IV (Patent) Challenges for CAMBIA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CAMBIA | Oral Solution (Sachet) | diclofenac potassium | 50 mg | 022165 | 1 | 2011-01-24 |
US Patents and Regulatory Information for CAMBIA
CAMBIA is protected by four US patents.
Patents protecting CAMBIA
Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAMBIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | See Plans and Pricing | See Plans and Pricing |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAMBIA
See the table below for patents covering CAMBIA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2007016072 | FORMULACIONES DE DICLOFENAC Y METODOS PARA USARLAS. (DICLOFENAC FORMULATIONS AND METHODS OF USE.) | See Plans and Pricing |
| South Korea | 101352130 | See Plans and Pricing | |
| New Zealand | 332655 | Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates | See Plans and Pricing |
| China | 101272768 | Diclofenac formulations and methods of use | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
